Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin

Autoimmunity Reviews

Volumn 3, Issue 3, 2004, Pages 221-227

  Aukrust, Pål ^a,b   Yndestad, Arne ^b   Damås, Jan Kristian ^a,b   Gullestad, Lars ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

Cytokines; Heart failure; Inflammation; Intravenous immunoglobulin

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; PIPERANOMETOZINE;

CLINICAL TRIAL; CORRELATION ANALYSIS; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CHRONIC DISEASE; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MYOCARDIAL CONTRACTION; PREDICTIVE VALUE OF TESTS;

EID: 1942489702     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00103-4     Document Type: Review

References (40)

1. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
2. Aukrust P., Ueland T., Lien E., Bendtzen K., Müller F., Andreassen A.K., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 83:1999;376-382.
3. Testa M., Yeh M., Lee P., Fanelli L., Loperfido F., Berman J.W. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 28:1996;964-971.
4. Damås J.K., Gullestad L., Aass H., Simonsen S., Fjeld J.G., Wikeby L., et al. Enhanced gene expression of chemockines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effects of intravenous immunoglobulin. J Am Coll Cardiol. 38:2001;187-193.
5. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
6. Damås J.K., Eiken H.G., Øie E., Bjerkeli V., Yndestad A., Ueland T., et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res. 47:2000;778-787.
7. Eiken H.G., Øie E., Damås J.K., Yndestad A., Bjerkeli V., Aass H., et al. Myocardial gene expression of leukemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest. 31:2001;389-397.
8. Wang Z.H., Liao Y.H., Fu M. The frequency of occurrence of autoantibodies against beta1-adrenoceptors and its clinical relevance in patients with hepatitis virus myocarditis. Autoimmunity. 34:2001;241-245.
9. Becker A.E., de Boer O.J., van Der Wal A.C. The role of inflammation and infection in coronary artery disease. Ann Rev Med. 52:2001;289-297.
10. Bachmaier K., Neu N., de la Maza, Pal S., Hessel A., Penninger J.M. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 283:1999;1335-1339.
11. Niebauer J., Volk H.-D., Kemp M., Dominguez M., Schumann R.R., Rauchhaus M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 353:1999;1838-1842.
12. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2:2001;675-680.
13. Frantz S., Kobzik L., Kim Y.D., Fukazawa R., Medzhitov R., Lee R.T., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 104:1999;271-280.
14. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 347:2002;185-192.
15. Okada M., Matsumori A., Ono K., Furukawa Y., Shioi T., Iwasaki A., et al. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;894-901.
16. Singal P.K., Khaper N., Palace V., Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res. 40:1998;426-432.
17. Baumgarten G., Knuefermann P., Kalra D., Gao F., Taffet G.E., Michael L., et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation. 105:2002;2192-2197.
18. Janabi M., Yamashita S., Hirano K., Sakai N., Hiraoka H., Matsumoto K., et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol. 20:2000;1953-1960.
19. Holm T., Damås J.K., Holven K., Nordøy I., Ueland T., Wæhre T., et al. CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells. J Thromb Haemost. 1:2003;257-262.
20. Blum A., Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med. 52:2001;15-27.
21. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol. 274:1998;R577-R595.
22. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 81:1997;627-635.
23. Bradham W.S., Bozkurt B., Gunasinghe H., Mann D., Spinale F.G. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 53:2002;822-830.
24. Kunisada K., Tone E., Fujio Y., Matsui H., Yamauchi-Takihara K., Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation. 98:1998;346-352.
25. Kunisada K., Negoro S., Tone E., Funamoto M., Osugi T., Yamada S., et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA. 97:2000;315-319.
26. Hirota H., Chen J., Betz U.A., Rajewsky K., Gu Y., Ross J. Jr, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 97:1999;189-198.
27. Sasayama S., Okada M., Matsumori A. Chemokines and cardiovascular diseases. Cardiovasc Res. 45:2000;267-269.
28. Kolattukudy P.E., Quasch T., Berges S. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol. 152:1998;101-111.
29. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:1998;524-525.
30. Gullestad L., Ueland T., Brunsvig A., Kjekshus J., Simonsen S., Frøland S.S., et al. Effect of ß-blockade on cytokine levels in chronic heart failure-a substudy in the MERIT-HF trial. Am Heart J. 141:2001;418-421.
31. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F.A., Blosch C., et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation. 99:1999;3224-3226.
32. Anker S.D., Coats A.J.S. How to recover from RENAISSANCE? The significance of the results from of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 86:2002;123-130.
33. Kadokami T., McTiernan C.F., Kubota T., Frye C.S., Bounoutas G.S., Robbins P.D., et al. Effects of soluble TNF receptor treatment on lipopolysaccaride-induced myocardial cytokine expression. Am J Physiol. 280:2001;H2281-H2291.
34. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 345:2001;747-755.
35. McNamara D.M., Rosenblum W.D., Janosko K.M., Trost M.K., Villaneuva F.S., Demetris A.J., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 95:1997;2476-2478.
36. Bozkurt B., Villaneuva F.S., Holubkov R., Tokarczyk T., Alvarez R.J. Jr, MacGowan G.A., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 34:1999;177-180.
37. Gullestad L., Aass H., Fjeld J.G., Wikeby L., Andreassen A.K., Ihlen H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 103:2001;220-225.
38. Aukrust P., Gullestad L., Lappegård K.T., Ueland T., Aass H., Wikeby L., et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation. 104:2001;1494-1500.
39. Andersson U., Bjork L., Skansen-Saphir U., Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev. 139:1994;21-42.
40. McNamara D.M., Holubkov R., Starling R.C., Dec G.W., Loh E., Torre-Amione G., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 103:2001;2254-2259.